| Name | Title | Contact Details |
|---|
Hyundai Motor Group Metaplant America (HMGMA) is an advanced automotive manufacturing facility located in Ellabell, Georgia. It serves as Hyundais third production hub in the U.S., complementing existing facilities in Alabama and Georgia. Designed as a Software Defined Factory, HMGMA integrates AI and robotics to support Hyundais vision for a technology-driven future in mobility. The facility spans 2,900 acres and will employ over 8,500 workers, with an additional 6,900 jobs created at off-site suppliers. HMGMA aims to produce 500,000 vehicles annually, including electric and hybrid models like the Hyundai IONIQ 5 and IONIQ 9. The plant represents a significant investment of approximately $12.6 billion, marking one of the largest economic development projects in Georgias history. HMGMA also emphasizes sustainability by utilizing hydrogen fuel-cell electric trucks for logistics, showcasing its commitment to environmentally responsible operations. The facility is expected to have a substantial economic impact, creating nearly 40,000 jobs in Georgia and supporting over 570,000 jobs nationwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Oden Machinery, Inc. provides customers worldwide with liquid filling and processing machinery backed by over three decades of industry-leading innovation in design and engineering solutions. Oden is a leading U.S. manufacturer of filling and processing machinery for the liquid products markets and provides complete turnkey liquid packaging lines. Custom designed systems for form/fill/seal, bag-in-box, retort, explosion proof, and other specialized liquid packaging applications are also available. In August 2010, Oden partnered with Green Frontier LLC to help companies optimize their liquid processing operations and reduce their impact on the environment. The Oden Process Equipment Group offers continuous stream digital blending systems, automated batch addition systems, and liquid product transfer systems, all designed to reduce labor costs, enhance product quality, increase production capacity, and decrease generation of waste and scrap. Our customers businesses span a broad range of industries, including pharmaceutical, personal care products, food processing, household products, general industrial, automotive products, petroleum products, and the chemical processing industries. If your packaging/processing operations include filling or processing liquid products, we encourage you to visit www.odencorp.com. If you need an off the shelf" machine or require highly specialized machinery give us a call, 800-658-3622.